Yulan Qi

发表

Impacts of Size on Pharmacokinetics and Biodistributions of Mebendazole Nanoformulations in Mice and Rats

Yulan Qi, 2008 .

A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria

D. Mould, Yulan Qi, D. Musson, 2014, Clinical Pharmacokinetics.

Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.

B. Schweighardt, A. Bagri, C. O’Neill, 2017, Journal of immunological methods.

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

B. Schweighardt, K. Larimore, B. Burton, 2021, Clinical and translational science.

Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.

C. Hendriksz, S. Santra, Yulan Qi, 2018, Molecular genetics and metabolism.

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.

A. Shaywitz, B. Schweighardt, C. O’Neill, 2015, Clinical therapeutics.

Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia

K. Larimore, M. Irving, J. Hoover-Fong, 2021, Clinical Pharmacokinetics.

Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

Yulan Qi, Jack G. Shi, C. Haller, 2018, Clinical Pharmacokinetics.

Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome

A. Shaywitz, B. Schweighardt, C. O’Neill, 2014, Clinical Pharmacokinetics.

Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.

M. Haskins, C. O’Neill, Yulan Qi, 2016, Molecular genetics and metabolism.

Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

Yulan Qi, Jack G. Shi, C. Haller, 2018, Clinical Pharmacokinetics.